High-, Moderate-, and Low-Intensity Statin Therapy* High Intensity Moderate Intensity Low Intensity LDL-C lowering Statins Atorvastatin mg (40 mg) Atorvastatin 10 mg Rosuvastatin (5 mg) mg Simvastatin Pravastatin 40 mg Lovastatin 40 mg Fluvastatin XL 80 mg Fluvastatin 40 mg BID Pitavastatin 1 4 mg Pravastatin mg Fluvastatin Percent LDL-C reductions with the primary statin medications used in clinical practice (atorvastatin, rosuvastatin, simvastatin) were estimated using the median reduction in LDL-C from the VOYAGER database.S3.2.1-2 Reductions in LDL-C for other statin medications (fluvastatin, lovastatin, pitavastatin, pravastatin) were identified according to FDA-approved product labeling in adults with hyperlipidemia, primary hypercholesterolemia, and Boldface type indicates specific statins and doses that were evaluated in RCTs,S3.2.1-3,S3.2.1-5 S3.2.1-16 and the Cholesterol Treatment All these RCTs demonstrated a reduction in major cardiovascular events. *Percent reductions are estimates from data across large populations. Individual responses to statin therapy varied in the RCTs and should be expected to vary in clinical practice.S3.2.1-2 LDL-C lowering that should occur with the dosage listed below each intensity. Evidence from 1 RCT only: down titration if unable to tolerate atorvastatin 80 mg in the IDEAL (Incremental Decrease through Aggressive Lipid Lowering) Although simvastatin 80 mg was evaluated in RCTs, initiation of simvastatin 80 mg or titration to 80 mg is not recommended by the FDA because of the increased risk of myopathy, including rhabdomyolysis. BID indicates twice daily; FDA, US Food and Drug Administration; LDL-C, low-density lipoprotein cholesterol; RCT, randomized controlled trial; VOYAGER, an indiVidual patient data meta-analysis Of statin therapY in At risk Groups: Effects of Rosuvastatin, atorvastatin and simvastatin; and XL, extended release. 